Author: Randy Osborne

Randy Osborne is a writer/editor for Deloitte Recap LLC. He worked with BioWorld for more than 11 years, and has contributed to Nature Biotechnology and other publications.

It’s True: Using More FDA ‘Wheels’ Under Cancer Drugs Can Speed Approval

Despite cancer’s complex nature, biotech firms have cranked out approvable therapies for the disease at an impressive pace, from blockbusters such as Genentech/Roche’s bevacizumab (Avastin) and trastuzumab (Herceptin) to smaller-selling but vital compounds targeting tumors that previously were treated inadequately or not at all. Clinical blowups abound, but the gains have been real. How do … Continue reading “It’s True: Using More FDA ‘Wheels’ Under Cancer Drugs Can Speed Approval”